About WIC
Get to know us
Who We Are
The World Immunotherapy Council (WIC) is an international organisation (with 26 global alliance societies across 23 countries/regions in the world) that focuses on advancing the field of immunotherapy, particularly in the context of cancer treatment. The council works to foster collaboration, share knowledge, and promote research in immunotherapy therapies, which harness the body’s immune system to fight diseases like cancer, autoimmune disorders, and infections. Immunotherapy has emerged as a promising treatment option for various types of cancer, and organisations like the WIC play a crucial role in bringing together experts, researchers, healthcare providers, and patients to drive progress in this area. The council helps to disseminate the latest scientific advancements, supports clinical trials, and advocates for the integration of immunotherapy into mainstream medical practices.
Defining the Critical Hurdles in Cancer Immunotherapy:
SITC strives to launch effective initiatives in order to accelerate the delivery of new immunotherapies to cancer patients around the world. In an effort led by SITC Past President, Bernard Fox, PhD, a collaborative group of international and domestic organisations similarly interested in promoting research and translation of cancer immunotherapy prepared a joint publication that defines the critical hurdles in cancer immunotherapy. This manuscript was published in the Journal of Translational Medicine.
2012 World Immunotherapy Council Summit in Curacao:
In an exciting and first-of-its-kind collaboration, SITC convened the World Immunotherapy Council (WIC) inaugural summit 21 – 24 February, 2012 in Curacao. Scientific sessions at the meeting focused on several of the hurdles identified in the “Defining the Critical Hurdles in Cancer Immunotherapy” manuscript, including mechanisms of immune escape, immunological monitoring, and prognostic and predictive biomarkers. This summit provided a forum to facilitate the rapid development and global dissemination of cancer immunotherapies through international scientific exchange.
Participating Society in the World:
- Asociación Colombiana de Inmunología (ACOI)
- Australia and New Zealand Society for Immunology (ASI)
- Canadian Cancer Immunotherapy Consortium (CCIC)
- Chinese American Hematology Oncology Network (CAHON)
- Chinese Society for Clinical Oncology (CSCO)
- Chinese Society for Immunology (CSI)/Tumor Immunotherapy and Biological Therapy (TIBT)
- French Society for Immunotherapy of Cancer (FITC)
- Hong Kong Cancer Therapy Society (HKCTS)
- Immuno-Oncology Society of India (I-OSI)
- Italian Network for Tumor Biotherapy (NIBIT)
- Japanese Association of Cancer Immunology (JACI)
- KWF working society-Dutch Tumor Immunology Meeting (KWF-DTIM)
- Korean Society of Medical Oncology (KSMO)
- Latin American and Caribbean Association for Immunology (ALACI)
- Malaysian Society for Biochemistry & Molecular Biology (MSBMB)
- Scandinavian Network for Immunotherapy of Cancer (SNIC)
- Singapore Society of Oncology - Cancer Immunotherapy Consortium (SSO-CIC)
- Sociedad Argentina de Inmunologia (SAI)
- Società Campana di ImmunoTerapia Oncologica (SCITO)
- Society for Immunotherapy of Cancer
- Spanish Group of Immuno-Biological Therapeutics in Cancer (GETICA)
- Thailand Hub of Talent for Cancer Immunotherapy (TTCI)
- The Taiwan Society for Immunotherapy of Cancer (TSITC)
- The Taiwanese Oncology Society (TOS)
- TransMed-VN (Vietnam)
- Tumor Immunology Meets Oncology (TIMO)
